What question did this study set out to answer?

To review the pharmacology, clinical trial evidence, and clinical utility of novel direct factor II and factor X inhibitors for the prophylaxis and treatment of venous thromboembolism.

May 21, 2009Current Vascular Pharmacology

New Anticoagulants: Focus on Venous Thromboembolism

View Full Paper

Ask AI

Bookmark

To review the pharmacology, clinical trial evidence, and clinical utility of novel direct factor II and factor X inhibitors for the prophylaxis and treatment of venous thromboembolism.
Synthesized pharmacological profiles of emerging oral and parenteral direct factor IIa and factor Xa inhibitors.
Evaluated clinical trial outcomes for short-term prophylaxis in orthopedic surgery and long-term anticoagulation compared with traditional vitamin K antagonists and heparins.
Direct oral agents, including dabigatran and rivaroxaban, demonstrated efficacy for venous thromboembolism prevention following total hip and knee replacement surgery.
Novel direct inhibitors provide predictable anticoagulation without the need for routine laboratory monitoring required by vitamin K antagonists or parenteral delivery required by heparins.

Structured PICO

Population

Patients requiring prophylaxis and treatment of venous thromboembolism (VTE) and/or arterial thromboembolism

Intervention

Novel anticoagulants including orally active direct factor II inhibitors, parenteral direct factor II inhibitors, orally active direct factor X inhibitors, and new parenteral FXa inhibitors

Comparator

Existing therapies including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, and oral vitamin K antagonists (VKA)

This review summarizes the pharmacology, clinical trial results, and potential advantages of new oral and parenteral anticoagulants for VTE prophylaxis and treatment over existing therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Enables first oral VTE prophylaxis options post-hip/knee replacement; leaves open comparative effectiveness and safety in broader populations.

Cite This Study

Gómez‐Outes et al. (2009) studied this question.

synapsesocial.com/papers/6a829e09a139900360239f89 https://doi.org/10.2174/157016109788340785

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Implication

Enables first oral VTE prophylaxis options post-hip/knee replacement; leaves open comparative effectiveness and safety in broader populations.

New Anticoagulants: Focus on Venous Thromboembolism

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

New Anticoagulants: Focus on Venous Thromboembolism

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Keep reading

Topics

Keep reading